Pierre Combe

8PUBLICATIONS
89CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

|Nov 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

Claudia Marchetti, Gwenael Ferron, Olivier Colomban

|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium.

Nicole Concin, Ioana Braicu, Pierre Combe

|Dec 14, 2024
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).

Florence Joly, Fernando Bazan, Delphine Garbay

|May 06, 2024
FASTOCH: Feasibility of Electronic Patient-Reported Outcomes in Older Patients With Cancer-A Multicenter Prospective Study.

Mathilde Cancel, Carine Sauger, Julie Biogeau

Pageof 2

Frequent Collaborators

2 joint publications

Eric Pujade-Lauraine

2 joint publications

Mathilde Cancel

2 joint publications

Isabelle Ray-Coquard

2 joint publications

Florence Joly